Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578695 | 1.00 | CYP2C19 (0.31) | CYP2C19MEN1KMT2A | |
| SCHEMBL845602 | 0.93 | — | — | |
| SCHEMBL845600 | 0.93 | — | — | |
| SCHEMBL9762967 | 0.93 | — | — | |
| SCHEMBL4422891 | 0.83 | — | — | |
| SCHEMBL5072354 | 0.77 | SLC6A1 (0.31) | — | |
| SCHEMBL28200533 | 0.76 | CYP2C19 (0.33) | CYP2C19MEN1KMT2A | |
| SCHEMBL23525345 | 0.76 | FFAR3 (0.32) | CYP2C19MEN1KMT2A | |
| SCHEMBL1966290 | 0.76 | CYP2C19 (0.30) | CYP2C19MEN1KMT2A | |
| SCHEMBL3009510 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403424-A1 | BIOACTIVE PHYTOCHEMICALS IN ZIZYPHUS AND GUARANA | PHYTOQUEST LTD (GB) | 2021-12-30 | — | — | US | disclosed |
| EP-3890729-A1 | BIOACTIVE PHYTOCHEMICALS IN ZIZYPHUS AND GUARANA | Phytoquest Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| WO-2020115475-A1 | BIOACTIVE PHYTOCHEMICALS IN ZIZYPHUS AND GUARANA | PHYTOQUEST LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| EP-2257286-B1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORP PLC (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2257286-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | Summit Corporation Plc (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009103953-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
| EP-0439444-A2 | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-07-31 | — | — | EP | disclosed |
| US-5013842-A | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | CYP2C19 2634/4885MEN1 1224/4885KMT2A 3165/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | CYP2C19 2634/4885MEN1 1224/4885KMT2A 3165/4885 |
| US-20210403424-A1 | BIOACTIVE PHYTOCHEMICALS IN ZIZYPHUS AND GUARANA | PRAP1, PEPD, PPIA | CYP2C19 281/4885MEN1 4378/4885KMT2A 209/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | CYP2C19 2634/4885MEN1 1224/4885KMT2A 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.